NCT03417544: Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

NCT03417544
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: Requires unequivocal evidence of new and/or progressive brain metastases- see trial for details
Exclusions: Known leptomeningeal or brainstem metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03417544

Comments are closed.

Up ↑